Supernus Pharma (SUPN) Reports Q4 Revenue of $155M

Supernus Pharma (NASDAQ: SUPN) reported Q4 revenue of $155 million versus the consensus estimate of $149.42 million.

GUIDANCE:

Supernus Pharma sees FY2022 revenue of $640-680 million, versus the consensus of $707.32 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth